Literature DB >> 15194175

Pathologic assessment of vasculopathies in pulmonary hypertension.

Giuseppe G Pietra1, Frederique Capron, Susan Stewart, Ornella Leone, Marc Humbert, Ivan M Robbins, Lynne M Reid, R M Tuder.   

Abstract

Pulmonary arterial hypertension (PAH) includes various forms of pulmonary hypertension of different etiology but similar clinical presentation and functional derangement. Histopathological vascular changes in all forms of PAH are qualitatively similar but with quantitative differences in the distribution and prevalence of pathological changes in various portions of the pulmonary vascular bed. The documentation of these topographic variations in the response of the pulmonary vasculature to injury may be important to understand the pathogenesis of the various subsets of PAH. To standardize the precise histopathological documentation of the pulmonary vasculopathy in PAH we propose a histopathological classification that includes both the predominant segment of the pulmonary vasculature affected and the possible coexistence of pathological changes in other vascular segments.

Entities:  

Mesh:

Year:  2004        PMID: 15194175     DOI: 10.1016/j.jacc.2004.02.033

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  164 in total

1.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

2.  Vascular compromise and hemodynamics in pulmonary arterial hypertension: model predictions.

Authors:  Zoheir Bshouty
Journal:  Can Respir J       Date:  2012 May-Jun       Impact factor: 2.409

3.  Nestin-expressing vascular wall cells drive development of pulmonary hypertension.

Authors:  Farhan Saboor; Ansgar N Reckmann; Claudia U M Tomczyk; Dorothea M Peters; Norbert Weissmann; Andre Kaschtanow; Ralph T Schermuly; Tatyana V Michurina; Grigori Enikolopov; Dieter Müller; Andrea Mietens; Ralf Middendorff
Journal:  Eur Respir J       Date:  2015-12-23       Impact factor: 16.671

4.  Pulmonary Arterial Stiffness: Toward a New Paradigm in Pulmonary Arterial Hypertension Pathophysiology and Assessment.

Authors:  Michal Schäfer; Cynthia Myers; R Dale Brown; Maria G Frid; Wei Tan; Kendall Hunter; Kurt R Stenmark
Journal:  Curr Hypertens Rep       Date:  2016-01       Impact factor: 5.369

5.  Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro.

Authors:  Zhaodong Li; Sergio A Jimenez
Journal:  Arthritis Rheum       Date:  2011-08

Review 6.  One hundred years of research in the pathogenesis of pulmonary hypertension.

Authors:  Ari Zaiman; Iwona Fijalkowska; Paul M Hassoun; Rubin M Tuder
Journal:  Am J Respir Cell Mol Biol       Date:  2005-11       Impact factor: 6.914

Review 7.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; John C Marecki; Amy Richter; Iwona Fijalkowska; Sonia Flores
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

8.  HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques.

Authors:  John C Marecki; Carlyne D Cool; Jane E Parr; Virginia E Beckey; Paul A Luciw; Alice F Tarantal; Angela Carville; Richard P Shannon; Adela Cota-Gomez; Rubin M Tuder; Norbert F Voelkel; Sonia C Flores
Journal:  Am J Respir Crit Care Med       Date:  2006-05-25       Impact factor: 21.405

9.  The aquaporin 1 C-terminal tail is required for migration and growth of pulmonary arterial myocytes.

Authors:  Ning Lai; Julie Lade; Kyle Leggett; Xin Yun; Syeda Baksh; Eric Chau; Michael T Crow; Venkataramana Sidhaye; Jian Wang; Larissa A Shimoda
Journal:  Am J Respir Cell Mol Biol       Date:  2014-06       Impact factor: 6.914

10.  Interleukin-6 overexpression induces pulmonary hypertension.

Authors:  M Kathryn Steiner; Olga L Syrkina; Narasaish Kolliputi; Eugene J Mark; Charles A Hales; Aaron B Waxman
Journal:  Circ Res       Date:  2008-12-12       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.